Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Scientific Reports|November 30, 2024
Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group studySerhat Sekmek, Sema Nur Ozsan Çelebi, Dogan Bayram, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology GroupArif Akyildiz, Melis Gultekin, Ecem Yigit, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 1, 2024
Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology GroupArif Akyildiz, Melis Gultekin, Ecem Yigit, et al.
Cancers|September 13, 2025
FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG)Ali Kalem, Tulay Kus, Taha Koray Sahin, et al.
Medical Oncology (Northwood, London, England)|August 11, 2014
The clinical and pathological features of 133 colorectal cancer patients with brain metastasis: a multicenter retrospective analysis of the Gastrointestinal Tumors Working Committee of the Turkish Oncology Group (TOG)Ozgur Tanriverdi, Esra Kaytan-Saglam, Sukran Ulger, et al.
Journal of Chemotherapy (Florence, Italy)|January 24, 2024
The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencingOsman Köstek, Ahmet Demirel, Muhammet Bekir Hacıoğlu, et al.
Therapeutic Advances in Medical Oncology|March 16, 2026
Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter studyTaha Koray Sahin, Fatih Kemik, Harun Muglu, et al.
Clinical Breast Cancer|April 7, 2025
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudySeda Kahraman, Enes Erul, Ozge Gumusay, et al.
Future Oncology (London, England)|May 3, 2023
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancerSeda Kahraman, Enes Erul, Mustafa Seyyar, et al.
Pageof 4